# A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Study · id `cardio:ct-nct01683409` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01683409](<https://clinicaltrials.gov/study/NCT01683409>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01683409

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

## Technical summary

Registry record NCT01683409. Randomized; double masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2017-07-02.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 130 participants (enrolled count; ClinicalTrials.gov record NCT01683409, source copy `cardio:ctgov-nct01683409-2019-09-30`, retrieved 2026-10-26)
- Start date: 2012-08 (registry gives no type) (ClinicalTrials.gov record NCT01683409, source copy `cardio:ctgov-nct01683409-2019-09-30`, retrieved 2026-10-26)
- Primary completion: 2014-09 (actual) (ClinicalTrials.gov record NCT01683409, source copy `cardio:ctgov-nct01683409-2019-09-30`, retrieved 2026-10-26)
- Completion: 2014-11 (actual) (ClinicalTrials.gov record NCT01683409, source copy `cardio:ctgov-nct01683409-2019-09-30`, retrieved 2026-10-26)
- Results first posted: 2017-07-02 (ClinicalTrials.gov record NCT01683409, source copy `cardio:ctgov-nct01683409-2019-09-30`, retrieved 2026-10-26)
- Countries: United States; Japan; Mexico; Puerto Rico (ClinicalTrials.gov record NCT01683409, source copy `cardio:ctgov-nct01683409-2019-09-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01683409-2019-09-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
- Condition: Diabetic Kidney Disease
- Intervention (Drug): Baricitinib
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY
- Collaborator: Incyte Corporation
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: fe2b2db1c7ac74440bd9be80738040f0b0c89a474231230f47a6a9b2fec866b9
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
